Video

Dr. Albala on the Advantages of PSMA-PET Imaging in Prostate Cancer

David Albala, MD, discusses the key advantages of utilizing PSMA-PET screening in clinical practice for patients with prostate cancer.

David Albala, MD, chief of urology, Crouse Hospital, discusses the key advantages of utilizing PSMA-PET screening in clinical practice for patients with prostate cancer.

The sensitivity and specificity of PSMA-PET scans are superior to that of current modalities used to identify prostate cancer, Albala says. These conventional imaging techniques, such as bone scans or CT scans, and the more recently developed fluciclovine (Axumin)-PET/CT scan have all contributed to advancements in this imaging technology.

Ultimately, PSMA-PET scans show promising diagnostic performance, and could completely change the current landscape of prostate cancer imaging. Moving forward, clinicians should aim to understand what this exciting new technology entails and consider how to best incorporate it into their current treatment strategies, Albala concludes.

Related Videos
Pamela L. Kunz, MD, associate professor, internal medicine (medical oncology), Yale School of Medicine; director, Center for Gastrointestinal (GI) Cancers, chief, GI Medical Oncology, Smilow Cancer Hospital, Yale Cancer Center
Matthew Matasar, MD, chief, Division of Blood Disorders, Rutgers Cancer Institute; professor, medicine, Rutgers Robert Wood Johnson Medical School
Kimberly Cannavale, MPH
Laurence Albigès, MD, PhD
Sattva S. Neelapu, MD
David L. Porter, MD
Suneel Kamath, MD
Craig E. Devoe, MD, MS
Yoshie Umemura, MD, division chief, Neuro-Oncology, William R. and Joan R. Shapiro Chair for Neuro-Oncology Research, associate professor, neurology, Barrow Neurological Institute, chief medical officer, Ivy Brain Tumor Center
Adam M. Burgoyne, MD, PhD, associate clinical professor, medicine, the University of California San Diego